TRX-214 / Therapex - LARVOL DELTA

TRX-214-1002, An antibody drug conjugate (ADC) targeting CD33 with a novel GSPT1 molecular glue for treatment of acute myeloid leukemia (AACR 2025) - "However, clinical development of GSPT1 MGDs, such as CC-885 and CC-90009, has been hampered by off-target toxicities...The in vitro and in vivo pharmacology of TRX-214-1002 were compared with ORM-6151 (another GSPT1 MG degrader-based CD33 ADC) and Mylotarg...Collectively, TRX-214-1002 highlighted the noticeable GSPT1 degradability and enhanced antileukemic activity, particularly in TP53 mutated and venetoclax-resistant AML cell lines, along with significant antitumor activity superior to competitor ADCs. Our preclinical data suggest that TRX-214-1002 has the high potential to provide a novel treatment strategy for CD33 positive relapse/refractory AML patients."

ADC • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Lung Cancer • Oncology • Solid Tumor • ATF3 • ATF4 • CD33 • FLT3 • GSPT1 • TP53

Terapex to present research results on 'targeted protein degrader antibody conjugate' at AACR 2025 [Google translation] (BioTimes) - "Terapex (CEO Lee Gu) announced on the 2nd that it had presented the research results of 'TRX-214-1002', a targeted protein degrader-antibody conjugate (DAC), in a poster presentation at the American Association for Cancer Research (AACR 2025) annual meeting held in Chicago, USA from the 25th to the 30th (local time)....In particular, 'TRX-214-1002' with the GSPT1 payload still showed cell growth inhibition activity in AML cell lines that were refractory to the existing AML treatment, the BCL-2 inhibitor 'venetoclax', confirming its potential as a second-line treatment....Experts present at the site noted the excellent decomposition ability of the GSPT1 payload, and evaluated that the GSPT1 payload showed superior tumor suppression effect even in the in vivo environment by rapidly and strongly degrading the target protein."

Preclinical • Acute Myelogenous Leukemia

Terapex to present research results on ‘target protein degrader antibody conjugate’ at AACR 2025 [Google translation] (BioTimes) - "Terapex will present the research results of its Target Protein Degrader-Antibody Conjugate (DAC), 'TRX-214-1002', for the first time on a global stage through a poster session to be held from 2 PM to 5 PM on the 27th. TRX-214-1002 is a next-generation ADC drug targeting acute myeloid leukemia (AML) that is refractory to existing treatments or has low drug response, and has been under development by Terapex since July of last year with support from the Korea Drug Development Fund (KDDF)."

Preclinical • Acute Myelogenous Leukemia